Proqr Therapeutics (PRQR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 17,996 | 20,457 | 7,050 | 4,253 | 1,602 |
| Gross Profit | 17,996 | 20,457 | 7,050 | 4,253 | 1,602 |
| Operating Expenses | 67,151 | 53,431 | 41,531 | 72,438 | 69,265 |
| Operating Income | -49,155 | -32,974 | -34,481 | -68,185 | -67,663 |
| Interest Expense | 1,456 | 1,173 | 1,578 | 5,402 | 4,029 |
| Other Income | 2,905 | 3,891 | 5,957 | 5,319 | -1,144 |
| Pre-tax Income | -47,706 | -30,256 | -30,102 | -68,268 | -72,835 |
| Income Tax | 22 | -213 | -84 | 101 | 138 |
| Net Income Continuous | -47,727 | -30,042 | -30,018 | -68,369 | -72,974 |
| Minority Interests | N/A | N/A | 416 | 232 | -70 |
| Net Income | $-47,727 | $-30,042 | $-30,433 | $-68,601 | $-72,904 |
| EPS Basic Total Ops | -0.45 | -0.35 | -0.38 | -0.96 | -1.14 |
| EPS Basic Continuous Ops | -0.45 | -0.35 | -0.37 | -0.95 | -1.14 |
| EPS Diluted Total Ops | -0.45 | -0.35 | -0.38 | -0.96 | -1.14 |
| EPS Diluted Continuous Ops | -0.45 | -0.35 | -0.37 | -0.95 | -1.14 |
| EPS Diluted Before Non-Recurring Items | -0.45 | -0.35 | -0.38 | -0.96 | -1.14 |
| EBITDA(a) | $-46,097 | $-29,986 | $-31,761 | $-65,529 | $-64,907 |